Drugmakers pledge faster, more equitable medicine access in Europe
Drugmakers have agreed to speed up the market launch of new drugs in underserved EU member states as an alternative to stricter regulation.
Members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) have agreed to a proposal designed to deliver faster, more equitable access to medicines across Europe.
From today, EFPIA member companies commit to file for pricing and reimbursement in all EU countries as soon as possible and no later than two years from the central EU market authorisation, provided that local systems allow it.
The lobby group says this will increase the availability of innovative medicines in Europe and decrease the amount of time patients spend waiting for new drugs by several months.
According to data published by EFPIA last week, the gap in the time it takes for patients to access new medicines in different EU member states is widening, with patients in Germany waiting 133 days on average compared to 899 days for patients in Romania.
There are also disparities in terms of availability of innovative medicines, with less than 30% of centrally approved products available in smaller and Eastern European member states, compared with 92% in Germany and 46% on average in the EU.
IQVIA modelling predicts that the commitment to file would increase the availability of medicines from 18% up to 64% in several countries. It also estimates a reduction in the time spent waiting for new medicines by up to five months in countries such as Bulgaria, Poland and Romania.
The commitment to file comes after EFPIA warned against proposed rules that would force drugmakers to bring products to all EU countries within a certain deadline. They say that regulation could backfire and discourage companies from bringing some products to the region’s public health systems altogether.
The group said: ‘We understand that some of the proposals being discussed could introduce obligations for (drugmaker) to market or supply all EU Member States.
The industry has concerns regarding the use of regulatory tools designed for medicines authorisation being applied to address availability issues that are within the remit of member states’.
In addition to the commitment to file, EFPIA said it was proposing an equity-based tiered pricing system, where the price of innovative medicines would vary depending on the country’s ability to pay.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance